Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy American Renal Associates stock

Learn how to easily invest in American Renal Associates stock.

American Renal Associates Holdings, Inc
NYSE: ARA - USD
DIAGNOSTICS & RESEARCH
$0
-

American Renal Associates Holdings, Inc is a diagnostics & research business based in the US. American Renal Associates shares (ARA) are listed on the NYSE and all prices are listed in US Dollars. American Renal Associates employs 4,977 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in American Renal Associates

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

American Renal Associates stock price (NYSE: ARA)

Use our graph to track the performance of ARA stocks over time.

American Renal Associates shares at a glance

Information last updated 2021-03-14.
52-week range$6.08 - $11.98
50-day moving average $11.47
200-day moving average $9.70
Wall St. target price$10.00
PE ratio N/A
Dividend yield $1.3 (11.3%)
Earnings per share (TTM) $-0.67

Buy American Renal Associates shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy American Renal Associates stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is American Renal Associates under- or over-valued?

Valuing American Renal Associates stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of American Renal Associates's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

American Renal Associates's PEG ratio

American Renal Associates's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into American Renal Associates's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

American Renal Associates's EBITDA

American Renal Associates's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $113.5 million.

The EBITDA is a measure of a American Renal Associates's overall financial performance and is widely used to measure a its profitability.

American Renal Associates financials

Revenue TTM $814.1 million
Operating margin TTM 9.73%
Gross profit TTM $254.5 million
Return on assets TTM 4.35%
Return on equity TTM 17.51%
Profit margin -1.11%
Book value $-2.50
Market capitalisation $397.9 million

TTM: trailing 12 months

Shorting American Renal Associates shares

There are currently 608,626 American Renal Associates shares held short by investors – that's known as American Renal Associates's "short interest". This figure is 50.4% down from 1.2 million last month.

There are a few different ways that this level of interest in shorting American Renal Associates shares can be evaluated.

American Renal Associates's "short interest ratio" (SIR)

American Renal Associates's "short interest ratio" (SIR) is the quantity of American Renal Associates shares currently shorted divided by the average quantity of American Renal Associates shares traded daily (recently around 155658.82352941). American Renal Associates's SIR currently stands at 3.91. In other words for every 100,000 American Renal Associates shares traded daily on the market, roughly 3910 shares are currently held short.

However American Renal Associates's short interest can also be evaluated against the total number of American Renal Associates shares, or, against the total number of tradable American Renal Associates shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case American Renal Associates's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 American Renal Associates shares in existence, roughly 20 shares are currently held short) or 0.0443% of the tradable shares (for every 100,000 tradable American Renal Associates shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against American Renal Associates.

Find out more about how you can short American Renal Associates stock.

American Renal Associates share dividends

We're not expecting American Renal Associates to pay a dividend over the next 12 months.

American Renal Associates share price volatility

Over the last 12 months, American Renal Associates's shares have ranged in value from as little as $6.08 up to $11.98. A popular way to gauge a stock's volatility is its "beta".

ARA.US volatility(beta: 1.11)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while American Renal Associates's is 1.1062. This would suggest that American Renal Associates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

American Renal Associates overview

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts. .

American Renal Associates in the news

There are no recent company news

Frequently asked questions

What percentage of American Renal Associates is owned by insiders or institutions?
Currently 9.145% of American Renal Associates shares are held by insiders and 80.775% by institutions.
How many people work for American Renal Associates?
Latest data suggests 4,977 work at American Renal Associates.
When does the fiscal year end for American Renal Associates?
American Renal Associates's fiscal year ends in December.
Where is American Renal Associates based?
American Renal Associates's address is: 500 Cummings Center, Beverly, MA, United States, 01915
What is American Renal Associates's ISIN number?
American Renal Associates's international securities identification number is: US0292271055
What is American Renal Associates's CUSIP number?
American Renal Associates's Committee on Uniform Securities Identification Procedures number is: 029227105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site